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Update on the Surgical Trial in Lobar Intracerebral
Haemorrhage (STICH II): statistical analysis plan
Barbara A Gregson1*, Gordon D Murray2, Patrick M Mitchell1, Elise N Rowan1, Anil R Gholkar3
and A David Mendelow1
Abstract
Background: Previous studies had suggested that the outcome for patients with spontaneous lobar intracerebral
haemorrhage (ICH) and no intraventricular haemorrhage (IVH) might be improved with early evacuation of the
haematoma. The Surgical Trial in Lobar Intracerebral Haemorrhage (STICH II) set out to establish whether a policy of
earlier surgical evacuation of the haematoma in selected patients with spontaneous lobar ICH would improve
outcome compared to a policy of initial conservative treatment. It is an international, multi-centre, prospective
randomised parallel group trial of early surgery in patients with spontaneous lobar ICH. Outcome is measured at six
months via a postal questionnaire.
Results: Recruitment to the study began on 27 November 2006 and closed on 15 August 2012 by which time 601
patients had been recruited. The protocol was published in Trials (http://www.trialsjournal.com/content/12/1/124/).
This update presents the analysis plan for the study without reference to the unblinded data. The trial data will not
be unblinded until after follow-up is completed in early 2013. The main trial results will be presented in spring 2013
with the aim to publish in a peer-reviewed journal at the same time.
Conclusion: The data from the trial will provide evidence on the benefits and risks of early surgery in patients with
lobar ICH.
Trial registration: ISRCTN: ISRCTN22153967
Update
Introduction
The Surgical Trial in Lobar Intracerebral Haemorrhage
(STICH II) aims to establish whether a policy of earlier
surgical evacuation of the haematoma in selected
patients with spontaneous lobar intracerebral haemor-
rhage (ICH) will improve outcome compared to a policy
of initial conservative treatment. The trial will also help
to better define the indications for early surgery.
This is an international multi-centre parallel group
trial with patients randomised to receive either ‘early
surgery’ (ES) or ‘initial conservative treatment’ (ICT).
Outcome is measured at six months by postal question-
naire to the patients.
Eligible patients have evidence of a spontaneous lobar
ICH on computed tomography (CT) scan (1 cm or less
from the cortical surface of the brain) with a volume of
between 10 and 100 ml, are within 48 hours of ictus,
have a best motor score on the Glasgow Coma Score
(GCS) of five or six and best eye score of two or more.
They are not eligible if there is clear evidence that the
haemorrhage is due to an aneurysm or angiographically
proven arteriovenous malformation, that it is secondary
to tumour or trauma, involves the basal ganglia, thal-
amic, cerebellar or brainstem regions, or if there is any
intraventricular blood. Patients should also not have any
severe pre-existing physical or mental disability or severe
co-morbidity that might interfere with assessment of
outcome. They should be able to have surgery within
12 hours if randomised to that group.
All patients who are randomised and have outcome
measured will be included in the analysis. Patients who
withdraw consent from the study will not be included.
The primary analysis will be ‘intention to treat’ with data
analysed according to the treatment group to which the
patient was randomised. This update to the published
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protocol [1] provides details of the statistical analysis
plan for STICH II.
Background to the statistical analysis of STICH II
Results from similar trials
Some early work was reported in the protocol from a
meta-analysis of individual patient data from previous
studies. This work has now been extended and published
[2]. In particular, the analysis of patients with only lobar
haematomas and no intraventricular haemorrhage (IVH)
using unfavourable outcome defined as dead, severely
disabled or independent inside the home shows a
tendency to favour surgery (Figure 1). This analysis
is dominated by the Surgical Trial in Intracerebral
Haemorrhage (STICH) [3], which was the motivation for
undertaking STICH II.
Further detailed analysis of data from the STICH study
In order to plan data analysis of STICH II, it is useful to
examine the data collected in the first STICH study [3]
for cases that would have been eligible for STICH II
under the present inclusion criteria.
In particular, the haematoma should be located in the
lobar region with no haematoma in the basal ganglia or
thalamus or in the ventricles and no more than 1 cm
from the cortex surface. The size of the haematoma
should be between 10 and 100 ml. The patient’s GCS
motor component at randomisation should be five or six
and the eye component two or more. The patient should
be within 48 hours of ictus.
For values of the size and location of blood in the
brain, we have available to us measures reported by the
local investigator at the time of randomisation and also
the assessments made by the central examiners from the
measurements made on the randomisation CT scan sup-
plied to us. Since it is the local investigator who decides
whether a patient is eligible or not, for this analysis the
measurements reported on the randomisation form will
be used. However, presence of IVH was not reported at
randomisation so that information will be taken from
the central assessment.
This selection provides 157 patients who had all the
inclusion criteria (78 randomised to ES and 79 to ICT).
Outcome at six months is available for 147 of these
patients (74 ES, 73 ICT). Of the ten lost patients, no
follow-up at all was obtained for six patients and four
patients were known to be alive at six months but died
before follow-up could be obtained so disability at six
months is unknown. There were a few discrepancies be-
tween the randomisation assessment and the central as-
sessment of haematoma characteristics. The depth from
the cortical surface exceeded 1 cm in four cases (max-
imum 1.8 cm). The volume was less than 10 ml in one
case (8.2 ml) and more than 100 ml in four cases (101.2,
101.7, 103.2 and 137.3).
Dichotomising the five-point Glasgow Outcome Scale
(GOS) at the usual point (good recovery (GR), moderate
disability (MD) versus severe disability (SD), vegetative
(V), dead (D)) gave 37% favourable outcome overall with
45% in the ES group and 30% in the ICT group (Fisher’s
exact P = 0.089, Pearson’s chi-squared = 0.070). Using
the prognostic-based outcome reported in the Lancet
paper [3] gives 41% favourable outcome overall (49% in
the ES group and 33% in the ICT group).
For the 147 patients with outcome assessment, the
two treatment groups were well matched on the usual
predictive variables of age <65 (42% ES and 42% ICT)
and volume >50 ml (31% ES and 32% ICT), but for GCS
13 to 15 (70% ES and 63% ICT) and whether the patient
was randomised within 12 hours (24% ES and 36% ICT),
there was evidence of some differences.
In the surgery group, 52 patients (70%) had surgery
within 12 hours, 2 patients did not receive surgery and 8
had surgery after 24 hours (26 to 49). In the initial con-
servative group, 25 (34%) had surgery, 8 within 12 hours
of randomisation and 13 had surgery after 24 hours.
Figure 1 Individual patient data meta-analysis of surgery versus conservative treatment for the subgroup of patients with lobar ICH
and no IVH. Reproduced from Gregson et al. [2].
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Dividing the prognostic score (10 x GCS – age –
0.64 x volume) according to the values of the quartiles and
comparing that with the eight-point GOS at six months
gives the result shown in Figure 2 for all patients in
STICH. (Values of the quartiles are −3.66, 27.672, 53.78)
Figure 3 shows the plot of eight-point GOS for only
those STICH patients who would have fulfilled the cri-
teria for STICH II plotted against the baseline risk score
quartiles (as calculated from all the patients in STICH).
Figure 3a shows the graph for number of respondents
and Figure 3b for the percentage of respondents.
Sample size in STICH II
In the protocol for STICH II, it is stated that with a 37%
favourable outcome from conservative treatment a sam-
ple size of 566 would be required to show a 12% benefit
from surgery (2P <0.05) with 80% power. A sample size
of 600 was therefore proposed to allow for withdrawals
and crossovers.
Randomisation procedures in STICH II
Patients are allocated according to a minimisation algo-
rithm based on age (three bands: <60, 60 to 69, 70+) and
neurological deficit in the worst affected arm or leg
(three bands: normal, weak, paralysed) with a random
component such that there is a 20% chance of the alloca-
tion being reversed. Patients are stratified by country
group and planned operation (two bands: craniotomy,
other). Sites are grouped by country (if we expected
many sites within a country to be included) or a country
group (if we expected only one site in the country).
Country groups were defined, as they arose, according to
geographic location.
Analysis statement in protocol for STICH II
The analysis statement in the protocol says: analysis will
be on an ‘intention to treat’ basis. The primary analysis
will be a simple categorical frequency comparison using
the chi-squared test for prognosis-based [4,5] favourable
and unfavourable outcomes at six months. Patients with
a good prognosis will be categorised as having a
favourable outcome if they achieve GR or MD on the
GOS. Patients with a poor prognosis will be categorised
as having a favourable outcome if they achieve GR, MD
or upper SD on the Glasgow Outcome Scale-Extended
(GOSE). Logistic regression analysis will be undertaken
to adjust for covariates. Secondary outcomes will also be
analysed using the prognosis-based method as specified
in STICH [3].
Statistics that will be reported
For categorical variables, the number and percentage in
each group will be reported. Percentages will be reported
to no decimal places. For continuous variables the me-
dian, quartiles, maximum and minimum will be
reported. Where P values are reported these will be to
three decimal places or at P <0.0001. The presence of
missing data will be reported.
Methods for statistical analyses to be reported in STICH II
Evaluation of demographics and baseline characteristics
Baseline characteristics will be reported separated by
treatment. The first table will include gender, age, pre-
ICH mobility, pre-ICH Rankin, time between ictus and
randomisation, GCS, neurological deficit in worst arm,
worst leg, and worst limb, speech, whether receiving any
anticoagulation or thrombolytic treatment prior to ictus,
past medical history and prognostic score. Prognostic
score will be derived as reported in STICH (10 x GCS –
age (years) – 0.64 x volume (ml)) with a cut point of
27.672 to differentiate between patients with a good
prognosis (score greater than cut point) and those with a
poor prognosis.
The second table will include details of site of haema-
toma, volume and depth from the site assessments plus
those and other measures from the central assessment.
Evaluation of treatment compliance and exposure
Crossovers will be reported. The third table will include
details of surgery for both groups including time from
ictus to surgery, and number and percentage operated
within 12 hours of ictus, time from randomisation to
surgery, method, any additional procedures, and status
prior to evacuation, whether sedated, GCS, and neuro-
logical status of worst arm, leg and speech. Reasons for
crossover will be reported. Amount of blood removed
during operation will be reported (as assessed by
l
Figure 2 Distribution of outcome by quartile of prognostic
index for all patients in STICH.
Gregson et al. Trials 2012, 13:222 Page 3 of 8
http://www.trialsjournal.com/content/13/1/222
differences in blood volume on randomisation scan and
on the five-day CT scan).
Outcome analysis
Outcomes will be reported as odds ratios with 95%
confidence interval reported to two decimal places
and P values to three decimal places. Absolute
benefits with 95% confidence intervals to one decimal
place will also be reported.
The primary outcome analysis will be a simple cat-
egorical frequency comparison using the chi-squared
test for prognosis-based favourable and unfavourable
outcomes on the eight-point GOS at six months. GOS
will be computed from the answers to the 14 ques-
tions as per the paper of Wilson, Edwards et al. [6]
a
b
Figure 3 Distribution of outcome by quartile of prognostic index for patients in STICH that would have been eligible for STICH II. (a)
Count of cases. (b) Percentage of cases.
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Where a response to a question is missing, the assess-
ment will be made using the responses to the other
questions. The allocation of outcome assessment will
be made prior to unblinding the treatment assignment.
Logistic regression analysis will be undertaken to adjust
for covariates age, GCS, volume of haematoma and neuro-
logical deficit.
Six-month outcome assessment may actually be made
any time after five months. Where it is very late, the
respondents are asked to answer the questions for an as-
sessment of the capabilities of the patient at the six-
month point. If a patient dies after six months but prior
to the six-month outcome being completed and it is im-
possible to obtain an assessment of the patient’s abilities
at six months, the patient will be excluded from analysis
of GOS.
Secondary outcome analysis will include Kaplan-Meier
survival curve with log-rank test, mortality at six
months, a prognosis-based modified Rankin score,
reporting of the eight-point GOS, Rankin and EuroQol
broken down by randomised treatment group.
Sensitivity analyses
An analysis based on a proportional odds model will be
undertaken as a sensitivity analysis. In addition, sensitiv-
ity analyses will be undertaken based on imputation of
missing outcome data.
Subgroup analysis
Odds ratios and 95% confidence intervals will be
reported for the following subgroups: age (two bands
using median split: <65, >=65), volume of haematoma
(using median split <= 35 ml, >35 ml), GCS (8 to 12, 13
to 15), time from ictus to randomisation (using median
split <21 hours, >=21 hours), severity of neurological
deficit - worse limb (normal, weak, paralysed), planned
method of haematoma removal (craniotomy, other).
Interaction tests will be undertaken and relevant
P values will be reported.
In addition, odds ratios will be reported by country
group and by whether the patients had been receiving
anticoagulant treatment prior to the haemorrhage.
Subsidiary analyses
Subsidiary analyses will be conducted although we rec-
ognise that any analysis by treatment received will be
biased and extremely difficult to interpret. They will not
be reported in the initial paper. Since delayed surgery is
permitted by the protocol, we will carry out two differ-
ent per protocol analyses excluding patients in the ICT
group who have surgery within a) 12 hours or within b)
48 hours:
a) Per protocol (12 hours) - only patients who received
the allocated treatment within 12 hours will be
included in this analysis. ES patients will have
received surgery within 12 hours or died within
12 hours. ICT patients will not have received surgery
within 12 hours.
b) Per protocol (surgery versus conservative) - only
patients who received the allocated treatment will be
included in this analysis. ES patients will have
received surgery within 12 hours. ICT patients will
not have received surgery within 48 hours.
Other analyses
In separate papers, the analysis of the CT scans will be
reported. Each CT scan will be read by two independent
blinded readers: a neuroradiologist and a neurosurgeon.
They are not informed as to whether the scan is a diag-
nostic scan or a five-day scan and the scans are coded
such that they cannot link two scans for one patient. Al-
though the readers will be able to identify if an operation
has been undertaken, they will not know which group
the patient was randomised to. They will report the loca-
tion and size of the haematoma, the presence of blood
in the ventricles, any midline shift or evidence of other
pathology. The inter-rater reliability will be reported.
Where there is evidence of disagreement, a third reader
will assess the scan. Percentage change in volume of
haematoma between the two scans will be compared
with outcome according to volume of haematoma on
the diagnostic scan.
Other issues
1. Incorrect randomisation. There have been a couple of
incidences when there have been problems with
randomisation. On several occasions, the database
manager was given information that the patient had
been randomised to one treatment but the
investigator had been told the other treatment by the
randomisation service. If the investigator acted on
the information from the randomisation service this
was correct. If the investigator acted on information
from the database manager then this was taken as
correct and the randomisation service was asked to
edit their database. This was a problem created by
the randomisation service in Aberdeen, which was
identified after a six-month period and affected three
patients.
2. Treatment allocation not heard. On seven occasions
the investigator reported that they did not hear the
treatment during the phone call (the phone cut out).
He/she then went through the system again resulting
in the patient being randomised twice. The
investigator then used the information from the
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second call. Sometimes this was the same and
sometimes different. If this happened during a
working day the database manager immediately
contacted the site and asked them to follow the
initial allocation. If it was not possible to make this
contact immediately then the second allocation was
used. In both cases, the randomisation service was
contacted to ensure the correct minimisation
algorithm was maintained. This occurrence was not
related to site.
3.Missing data. Missing data are rare because sites are
contacted to ensure that all data collected by two
weeks is available. Sometimes a randomisation CT
was not obtained because the patient took it home
with them before it was copied or it had been done
at an outlying hospital and a copy could not be
obtained. For these cases, it will not be possible to
estimate change in volume of the haematoma by
treatment as estimated by blinded raters. Missing
outcome information has been addressed above.
4. Protocol variations. Some patients may have been
recruited who were later found to have been
ineligible (central assessment of the CT scan may
identify the haematoma as being outside the eligible
volume or there might be evidence of blood in the
ventricles or of a bleed involving deeper structures,
or caused by other mechanisms). These will be
detailed but included in all analyses as if
appropriately recruited.
Discussion and timetable
Patients were recruited to the trial between 27 Novem-
ber 2006 and 15 August 2012. In total, 601 patients were
recruited. Follow-up of recruited patients will continue
through 2012 and into 2013. The trial data will be
unblinded in early 2013 once data collection is complete
and the dataset is closed. The main trial results will be
presented in the spring of 2013. The aim will be to pub-
lish the results at the same time or soon after.
List of all registered recruiting collaborating centres:
ARMENIA - Yerevan State Medical University, Dr
Ruben V Fanarjyan
AUSTRALIA - Royal Melbourne Hospital, Prof
Stephen Davis
AUSTRIA - Rudolfstiftung Hospital, Vienna, Dr
Günther Kleinpeter
Medical University of Vienna, Prof Andreas Gruber
CANADA - University of Alberta Hospital, Edmonton,
Dr Max Findlay
CHINA - Tianjin Medical University General Hospital,
Prof Shuyuan Yue
Beijing Tiantan Hospital, Dr Yuanli Zhao
Huashan Hospital, Fudan University, Shanghai,
Prof Dr Ying Mao
CZECH REPUBLIC - Central Military Hospital,
Prague, Prof Vladimir Benes
Fakultni Nemocnice, Ostrava, Dr Tomas Krejci
University Hospital, Brno, Prof Martin Smrcka
St. Anne's University Hospital, Brno, Prof Dr Pavel
Cejpak
Fakultni Nemocnice, Olomouc, Prof Miroslav Vaverka
Regional Hospital, Liberec, Dr Pavel Buchvald
EGYPT - Mansoura International Hospital, Dr
Abd-Elhafiz Shehab Eldien
Zagazig University Hospital, Dr Mohamed Barakat
Alexandria University Hospital, Prof Osama Abdelaziz
GEORGIA - State Medical University Clinic, Tbilisi,
Prof Alexander Gvelesiani
GERMANY - Klinik fur Neurochirurgie, Magdeburg
University, Prof Dr Raimund Firsching
Clemens Hospital, Munster, Prof Dr Abolghassem
Sepehrnia
Universitatsklinikum Erlangen, Prof Dr Michael
Buchfelder
Klinikum Amberg, Dr Andrea Kleindienst
Heinrich Heine University, Duesseldorf, Dr Daniel
Haenggi
University Hospital Heidelberg, Dr Karl Kiening
University Clinic, Munster, Prof Walter Stummer
Klinikum Kassel, Prof Dr Wolfgang Deinsberger
Ernst Moritz Arndt University, Greifswald, Prof Dr
W S Schroeder
University Schleswig-Holstein, Lubeck, Dr Georg
Nowak
Helios Klinikum Berlin Buch, Prof Dr Jurgen Kiwit
Neurochirurgische Klinik, Dessau, Dr Kazimierz
Sadowy
Universitatsklinikum des Saarlandes, Prof Wolf-Ingo
Steudel
Dr. Horst Schmidt Kliniken, Wiesbaden, Prof Gerhard
Hamman
Klinikum Saarbrucken, Winterberg, Dr S Thomas
Charite - University Medicine, Berlin, Prof Eric Juettler
Universitatsklinikum Jena, Dr Albercht Waschke
Asklepios Klinik Altona, Prof Dr Uwe Kehler
Diakonieklinikum, Jun-Stilling Hospital, Siegen,
Dr Veit Braun
GREECE - Ippokration General Hospital, Aristotle
University, Thessaloniki, Prof Philippos Tstitsopoulos
Evangelismos Hospital, Athens, Mr George Stranjalis
AHEPA General Hospital, Aristotle University,
Thessaloniki, Dr Athanasios Spiliotopoulos
HUNGARY - Pecs University Hospital, Dr Andras
Buki
Borsod County and University Teaching Hospital,
Dr Jozsef Dobai
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INDIA - All India Institute of Medical Sciences,
New Delhi, Dr P Sarat Chandra
BGS Global Hospital, Bangalore, Dr Shailesh Rao
Christian Medical College and Hospital, Ludhiana,
Dr Sarvpreet Singh Grewal
National Neurosciences Centre, Kolkata, Dr K Sridhar
Care Hospital, Visakhapatnam, Dr V P Ramana
Care Hospitals Institute of Neurological Sciences,
Hyderabad, Dr T V R K Murthy
Kerala Institute of Medical Sciences, Dr Moni Vinod
Acharya Vinoba Bhave Rural Hospital, Maharashtra,
Dr Anand Kakani
Kamineni Hospital, Hyderabad, Dr Subodh Raju
Amri Hospital, Dhakuria, Prof R N Bhattacharya
MM Institute of Medical Sciences and Research,
Haryana, Prof Amit Agrawal
Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, Dr Suresh Nair
National Institute of Mental Health and Neuro
Sciences, Bangalore, Dr B Indira Devi
ISRAEL - Rambam Hospital, Haifa, Dr Leon Levi
Sheba Medical Center, Dr Sagi Harnof
ITALY - University Sapienza, Rome, Prof Robert
Delfini
JAPAN - Kanto Medical Center, NTT East Co. Tokyo,
Dr Akio Morita
Hirosaki University School of Medicine, Professor
Norihito Shimamura
LATVIA - Clinical University Hospital, Gailezers, Riga,
Dr Kaspars Auslands
Pauls Stradins Clinical University Hospital, Riga, Prof
Egils Valeinis
LITHUANIA - Klaipeda University Hospital, Prof
Antanas Gvazdaitis
Kaunas University Hospital, Dr Antanas Gvazdaitis
MACEDONIA - Clinical Center, Skopje, Prof Dr Kiril
Lozance
MALAYSIA - Universiti Sains Malaysia, Kubang
Kieran, Prof Dr Jafri Malin
Hospital Sultanah Aminah, Johor Bahru, Dr Noor
Azman Abdul Rahman
MEXICO - Instituto Nacional de Neurologia y
Neurochirugia, Tlalpan, Dr Samuel Romero Vargas
Hospital Civil de Guadalajara, Dr Jose Luis
Ruiz-Sandoval
MOLDOVA - National Practical and Scientific Centre
of Emergency Medicine, Chisinau, Prof Stanislaw
Groppa
NEPAL - B. P. Koirala Institute of Health Sciences,
Dharan, Dr Yam Bahadur Roka
B & B Hospital, Gwarko, Lalitpur, Dr Krishna Sharma
NORWAY - St Olavs Hospital, Trondheim University
Hospital, Dr Sozaburo Hara
PAKISTAN - Lahore General Hospital, Dr Khalid
Mahmood
NW General Hospital and Research Centre, Peshawar,
Prof Tariq Khan
POLAND - Poznan University of Medical Sciences,
Prof Dr Stanislaw Nowak
University Medical School, Bialystok, Prof Zenon
Mariak
ROMANIA - Cluj County Emergency Hospital,
Cluj-Napoca, Prof Ioan Stefan Florian
Country Hospital, Timisoara, Dr Horia Ples
RUSSIA - Novosibirsk Medical University, Prof Alex
Krivoshapkin
SAUDI ARABIA - King Khalid University Hospital,
Riyadh, Dr Essam A Elgamal
SINGAPORE - National University Hospital,
Dr Chou Ning
SOUTH AFRICA - Steve Biko Academic Hospital,
Pretoria, Professor Sam Mokgokong
SOUTH KOREA - National Medical Center, Seoul,
Prof Dae Hee Han
SPAIN - Hospital Universitario 'Marques de Valdecilla',
Santander, Prof Alfonso Vazquez-Barquero
Hospital Universitario Virgen de las Nieves, Granada,
Dr Majed J Katati
Hospital Clinico Universitario, Valladolid, Dr Rosario
Sarabia
Hospital de Cruces, Bilbao, Prof Jesus Garibi
Undabarra
Germans Trias I Pujol University Hospital, Barcelona,
Dr Carlos Alonso
Hospital Universitario Rio Hortego, Valladolid,
Dr Rosario Sarabia
University Son Espases, Majorca, Dr Javier Ibanez
University Hospital Murcia, Dr Marcelo Galarza
SRI LANKA - National Hospital of Sri Lanka,
Colombo, Dr H D S Kularathne
SWEDEN - Akademiska Sjukhuset, Uppsala,
Prof Per Enblad
TAIWAN - Taipei Medical University Hospital,
Dr Kuo-Hsing Liao
THE NETHERLANDS - University Medical Centre,
Groningen, Dr Gert-Jan Luijckx
TURKEY - University of Istanbul, Prof Orhan Barlas
UK - Ninewells Hospital, Dundee, Professor M Sam
Eljamel
Radcliffe Infirmary, Oxford, Mr Richard Kerr
Hurstwood Park, Haywards Heath, Mr Giles Critchley
James Cook University Hospital, Middlesbrough,
Mr Roger Strachan
The National Hospital for Neurology and
Neurosurgery, London, Mr Laurence Watkins
Aberdeen Royal Infirmary, Dr Pragnesh Bhatt
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Southampton University Hospital, Mr Antonio Belli,
Mr Diederik Bulters
Addenbrooke's Hospital, Cambridge, Mr Peter
Kirkpatrick
Newcastle General Hospital and Royal Victoria
Infirmary, Newcastle, Mr John Crossman
Leeds General Infirmary, Mr Jake Timothy
Morriston Hospital, Swansea, Mr Robert Redfern
Salford Royal Infirmary, Mr Andrew King
Preston Royal Infirmary, Mr Aprajay Golash, Mr Nihal
Gurusinghe
Western General Hospital, Edinburgh, Dr Rustam
al-Shahi Salman
St. George's Hospital (Atkinson Morley's), London,
Prof B A Bell
The Walton Centre, Liverpool, Mr Mohsen Javadpour,
Mr Paul Eldridge
University Hospital of North Staffordshire, Mr Simon
Shaw
Hull Royal Infirmary, Mr Shailendra Achawal
USA - Research Medical Center, Kansas, Dr Iftekar
Ahmed
Hartford Hospital, Dr Inam Kureshi
Loyola University Hospital, Chicago, Dr Michael
Schneck
Temple University Hospital, Philadelphia, Dr Michael
Weaver
Central Illinois Neuroscience Foundation,
Bloomington, Dr Keith Kattner
Georgia Neurosurgical Institute, Macon, Dr Arthur
Grigorian
Albany Medical Centre, Dr John German
Mayo Clinic, Jacksonville, Dr Benjamin Eidelman
Penn State Hershey Medical Centre, Dr Kevin
Cockroft
University of Louisville and Baptist Hospital East,
Dr Jonathan E Hodes
University of Virginia Medical Center, Charlottesville,
Dr Kenneth Liu
St. Joseph’s Candler Health System, Savannah, Dr Jay
Howington
University of Illinois Medical Center at Chicago,
Dr Sepidah Amin-Hanjani
Washington University School of Medicine,
Dr Gregory Zipfel
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